The S&P 500 fades despite tech rally — plus, the crosscurrents driving Lilly's volatile day

The S&P 500 turned negative Thursday, primarily due to President Trump's public letters to 17 pharmaceutical companies, including Eli Lilly and Bristol Myers Squibb, demanding drug price cuts, which pressured the sector. This overshadowed positive post-earnings moves from Meta Platforms and Microsoft, with Microsoft briefly nearing a $4 trillion market capitalization. Broader market sentiment was also influenced by Federal Reserve caution on interest rate cuts due to tariff concerns and ongoing global trade negotiations. Separately, Eli Lilly announced positive Phase 3 SURPASS-CVOT trial results for Mounjaro, demonstrating cardiovascular risk reduction in Type 2 diabetes, potentially expanding its label, though the stock remained pressured by Trump's actions and upcoming earnings focus on GLP-1 sales guidance. Investors now anticipate key earnings reports from major tech firms and Friday's nonfarm payroll data.

Analysis

The S&P 500 experienced a reversal into negative territory, primarily driven by political pressure on the pharmaceutical sector. President Trump's public call for price cuts, specifically targeting firms including Eli Lilly (LLY) and Bristol Myers Squibb (BMY), introduced significant regulatory uncertainty and weighed heavily on healthcare stocks. This headwind overshadowed strong post-earnings performance from key technology names, with Meta Platforms (META) surging 12% and Microsoft (MSFT) rising 4%, briefly touching a $4 trillion market capitalization. Broader market sentiment remains cautious, influenced by Federal Reserve uncertainty regarding a September interest rate cut due to potential inflationary effects of tariffs, and ongoing trade negotiations with China and Mexico. For Eli Lilly, the political pressure eclipsed positive clinical news from its SURPASS-CVOT Phase 3 trial, which confirmed Mounjaro as a viable alternative for Type 2 diabetes patients with cardiovascular risk. While this result could lead to a label expansion and broader insurance coverage, the market's focus remains squarely on the upcoming earnings report for forward guidance on GLP-1 drug sales, a catalyst amplified by Novo Nordisk’s recent guidance cut.

Key Decisions for Investors

• Investors should exercise caution with pharmaceutical holdings like Eli Lilly and Bristol Myers Squibb, as direct political pressure on drug pricing has created a significant valuation headwind that can override positive fundamental developments.
• Monitor Eli Lilly's upcoming earnings release closely, as management's guidance on Mounjaro and Zepbound sales will be a more critical determinant of stock performance than the recent, albeit positive, trial results.
• Despite strong earnings from mega-cap tech providing pockets of strength, the market's inability to sustain gains indicates underlying fragility; watch for key macroeconomic data like the nonfarm payroll report and any developments on trade tariffs to gauge broader market direction.